Insider Selling: Syneos Health Inc (SYNH) CEO Sells 8,143 Shares of Stock
Syneos Health Inc (NASDAQ:SYNH) CEO Alistair Macdonald sold 8,143 shares of Syneos Health stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $53.00, for a total value of $431,579.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Alistair Macdonald also recently made the following trade(s):
- On Tuesday, February 5th, Alistair Macdonald sold 6,697 shares of Syneos Health stock. The stock was sold at an average price of $53.04, for a total value of $355,208.88.
SYNH stock opened at $53.88 on Friday. Syneos Health Inc has a 1-year low of $31.10 and a 1-year high of $54.19. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.97 and a quick ratio of 0.97. The stock has a market capitalization of $5.46 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 1.48 and a beta of 1.51.
SYNH has been the topic of several recent research reports. SunTrust Banks cut their target price on Syneos Health to $55.00 and set a “buy” rating on the stock in a report on Wednesday, December 19th. Zacks Investment Research downgraded Syneos Health from a “buy” rating to a “hold” rating in a report on Friday, November 30th. ValuEngine raised Syneos Health from a “hold” rating to a “buy” rating in a report on Saturday, November 10th. Barclays cut their target price on Syneos Health from $51.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, January 3rd. Finally, Robert W. Baird set a $60.00 target price on Syneos Health and gave the stock a “buy” rating in a report on Tuesday, January 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Syneos Health has a consensus rating of “Buy” and a consensus price target of $53.44.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.